Study of Gemcitabine Chemoradiation and TNP-470 Patients Locally Advanced, Nonmetastatic Adenocarcinoma of Pancreas

Phase 2

Terminated

• Conditions: Pancreatic Neoplasms
• Interventions: Drug: TNP-470

• Registration Number: NCT00038701
• Lead Sponsor: M.D. Anderson Cancer Center

Brief Summary

The goal is to assess survival and patterns of failure in patients treated with Gemzar-based chemoradiation and TNP-470 for locally advanced adenocarcinoma of the pancreas.

Detailed Description

Not available

Study Timeline

• Study Start: 1999-08
• Study First Submitted: 2002-06-04
• Study First Submitted QC: 2002-06-04
• Study First Posted: 2002-06-05
• Primary Completion: 2004-05-11
• Study Completion: 2004-05-11
• Status Verified: 2018-10
• Last Update Submitted: 2018-10-31
• Last Update Posted: 2018-11-01

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Gemzar Chemoradiation + TNP-470	TNP-470	-

Primary Outcome Measures

Name	Time	Method
Patient Survival Rate	2 years

Trial Locations

Locations (1)

UT MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States